newsfilter
← Latest News
GlobeNewswire·

Apollomics Reports First Half 2023 Financial Results and Provides Corporate Update

Phase 2 data from vebreltinib (APL-101), a highly selective cMet inhibitor, in patients with NSCLC with MET exon14 skipping mutation expected second half 2023 Approximately $52.6 million in cash, cash equivalents, and